On June 7, 2023, the Food and Drug Administration’s (“FDA”) Office of Prescription Drug Promotion (“OPDP”) issued its first Untitled Letter of the year regarding violative promotional materials for a prescription drug indicated for the treatment of endogenous hypercortisolemia (high cortisol) in adults with Cushing’s syndrome. Specifically, OPDP alleged that a website promoting the... READ MORE
The Wait Is Over . . . OPDP Issues Its First Untitled Letter of 2023
Posted on July 14, 2023 in Health Law News
Published by: Hall Render
